Drug intelligence / Profile preview

TLD-003

Development stage: Unknown
Lead developer: Tilde Sciences

Overview

TLD-003 is an investigational drug candidate currently in Phase 1 clinical development by Tilde Sciences. It is part of the company's 'Select Metabolism Pipeline,' which focuses on addressing unmet medical needs in rare metabolic disorders. As of early 2024, specific details regarding the drug's molecular target, modality (such as whether it is a small molecule or biologic), and precise mechanism of action have not been publicly disclosed by the developer. The candidate is part of a broader portfolio of rare disease treatments being advanced by Tilde Sciences, the successor company to Vyera Pharmaceuticals.

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on TLD-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLD-003.

Explore the full profile